Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - GoodwillEBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Akari Therapeutics (AKTX) Receivables - Net (2011 - 2013)

Akari Therapeutics recorded quarterly Receivables - Net of $6000.0 in Q4 2013, down 50.0% quarter-over-quarter from $12000.0 in Q4 2012, and down 50.0% year-over-year from $12000.0 in Q4 2012.

Akari Therapeutics' Receivables - Net history runs 3 years deep, the most recent figure standing at $6000.0 for Q4 2013.

  • In Q4 2013, Receivables - Net fell 50.0% year-over-year to $6000.0; the TTM figure through Dec 2013 stood at $6000.0 (down 50.0% YoY), while the FY2013 annual figure was $6000.0, down 50.0% from the prior year.
  • Receivables - Net came in at $6000.0 for Q4 2013 at Akari Therapeutics, down from $12000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $19000.0 in Q4 2011 to a low of $6000.0 in Q4 2013.
  • A 3-year average of $12333.3 and a median of $12000.0 in 2012 frame the typical range for Receivables - Net.
  • Across the five-year window, Receivables - Net plunged 36.84% in 2012 and tumbled 50.0% in 2013, its largest moves.
  • Akari Therapeutics' Receivables - Net stood at $19000.0 in 2011, then plunged by 36.84% to $12000.0 in 2012, then sank by 50.0% to $6000.0 in 2013.
  • According to Business Quant data, Receivables - Net over the past three periods registered $6000.0, $12000.0, and $19000.0 for Q4 2013, Q4 2012, and Q4 2011 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2013 6,000.00
Dec 31, 2013 6,000.00
Dec 31, 2012 12,000.00
Dec 31, 2012 12,000.00
Dec 31, 2011 19,000.00
Dec 31, 2011 19,000.00